Loading...
XNASFBLG
Market cap66mUSD
Jan 16, Last price  
1.91USD
1D
-5.45%
1Q
-43.66%
IPO
-89.09%
Name

Fibrobiologics Inc

Chart & Performance

D1W1MN
XNAS:FBLG chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-16m
L+221.91%
-1,582,000-5,121,000-16,485,000
CFO
-6m
L+57.43%
-1,410,000-4,066,000-6,401,000

Profile

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
URL
https://fibrobiologics.com/
IPO date
Jan 31, 2024
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFY
2023‑122022‑122021‑12
Income
Revenues
Cost of revenue
9,326
4,467
Unusual Expense (Income)
NOPBT
(9,326)
(4,467)
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
(9,326)
(4,467)
Net income
(16,485)
221.91%
(5,121)
223.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
16,138
2,150
BB yield
Debt
Debt current
362
5,777
Long-term debt
3,132
3,494
Deferred revenue
Other long-term liabilities
Net debt
(5,669)
7,005
Cash flow
Cash from operating activities
(6,401)
(4,066)
CAPEX
(495)
Cash from investing activities
(495)
Cash from financing activities
13,793
5,925
FCF
(9,733)
(6,666)
Balance
Cash
9,163
2,266
Long term investments
Excess cash
9,163
2,266
Stockholders' equity
(24,356)
(6,410)
Invested Capital
27,356
9,938
ROIC
ROCE
EV
Common stock shares outstanding
28,231
32,492
Price
Market cap
EV
EBITDA
(8,889)
(4,373)
EV/EBITDA
Interest
147
654
Interest/NOPBT